2.Olson, CK, et al. Epidemiology of Campylobacter jejuni infections in industrialized nations. In: Nachamkin, I, Szymanski, CM and Blaser, MJ, eds. Campylobacter, 3rd edn. Washington DC: ASM Press, 2008, pp. 163–189.
3.Swartz, MN. Human diseases caused by foodborne pathogens of animal origin. Clinical Infectious Diseases 2002; 34 (Suppl. 3): S111–S122.
4.European Food Safety Authority, European Centre for Disease Prevention and Control. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2010. EFSA Journal 2012; 10: 2597.
5.Haagsma, JA, et al. Disease burden of post-infectious irritable bowel syndrome in The Netherlands. Epidemiology and Infection 2010; 138: 1–7.
6.Thabane, M, Marshall, JK. Post-infectious irritable bowel syndrome. World Journal of Gastroenterology 2009; 15: 3591–3596.
7.Allos, BM. Campylobacter jejuni infections: update on emerging issues and trends. Clinical Infectious Diseases 2001; 32: 1201–1206.
8.Blaser, MJ, Engberg, J. Clinical aspects of Campylobacter jejuni and Campylobacter coli infections. In: Nachamkin, I, Szymanski, CM and Blaser, MJ, eds. Campylobacter, 3rd edn.Washington DC: ASM Press, 2008, pp. 99–121.
9.Smith, JL, Fratamico, PM. Fluoroquinolone resistance in Campylobacter. Journal of Food Protection 2010; 73: 1141–1152.
10.Scharff, RL. Economic burden from health losses due to foodborne illness in the United States. Journal of Food Protection 2012; 75: 123–131.
11.Gupta, A, et al. Antimicrobial resistance among Campylobacter strains, United States, 1997–2001. Emerging Infectious Diseases 2004; 10: 1102–1109.
12.Guerrant, RL, et al. Practice guidelines for the management of infectious diarrhea. Clinical Infectious Diseases 2001; 32: 331–351.
13.Aberg, JA, et al. Infectious Diseases Handbook. Canada: Lexi-Comp, 2006.
14.Kapperud, G, et al. Clinical features of sporadic Campylobacter infections in Norway. Scandinavian Journal of Infectious Diseases 1992; 24: 741–749.
15.Ternhag, A, et al. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clinical Infectious Diseases 2007; 44: 696–700.
16.Nachamkin, I, Szymanski, CM, Blaser, MJ (eds). Campylobacter. Washington DC, USA: ASM Press, 2008.
17.Deckert, AE, et al. Antimicrobial resistance and antimicrobial use associated with laboratory-confirmed cases of Campylobacter in two health unit areas. Canadian Journal of Infectious Diseases and Medical Microbiology (in press).
18.Gantz, NM, et al. Manual of Clinical Problems in Infectious Disease. Philadelphia: Lippincott Williams and Wilkins, 2006.
19.Engberg, J, et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerging Infectious Diseases 2001; 7: 24–34.
20.King, A, Phillips, I. A comparison of the in-vitro activity of clarithromycin, a new macrolide antibiotic, with erythromycin and other oral agents. Journal of Hospital Infection 1991; 19 (Suppl. A): 3–9.
21.Hosmer, DW, Royston, P. Using Aalen's linear hazards model to investigate time-varying effects in the proportional hazards regression model. Stata Journal 2002; 2: 331.
22.The Campylobacter Sentinel Surveillance Scheme Collaborators. Ciprofloxacin resistance in Campylobacter jejuni: case-case analysis as a tool for elucidating risks at home and abroad. Journal of Antimicrobial Chemotherapy 2002; 50: 561–568.
23.Robins-Browne, RM, et al. Treatment of acute nonspecific gastroenteritis of infants and young children with erythromycin. American Journal of Tropical Medicine and Hygiene 1983; 32: 886–890.
24.Mandal, BK, et al. Double-blind placebo-controlled trial of erythromycin in the treatment of clinical Campylobacter infection. Journal of Antimicrobial Chemotherapy 1984; 13: 619–623.
25.Anders, BJ, et al. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982; 1: 131–132.
26.Robins-Browne, RM, et al. Treatment of Campylobacter-associated enteritis with erythromycin. American Journal of Diseases of Children 1983; 137: 282–285.
28.Effler, P, et al. Sporadic Campylobacter jejuni infections in Hawaii: associations with prior antibiotic use and commercially prepared chicken. Journal of Infectious Diseases 2001; 183: 1152–1155.
29.Vukelic, D, Trkulja, V, Salkovic-Petrisic, M. Single oral dose of azithromycin versus 5 days of oral erythromycin or no antibiotic in treatment of Campylobacter enterocolitis in children: a prospective randomized assessor-blind study. Journal of Pediatric Gastroenterology and Nutrition 2010; 50: 404–410.
30.Levesque, S, Frost, E, Michaud, S. Comparison of antimicrobial resistance of Campylobacter jejuni isolated from humans, chickens, raw milk, and environmental water in Quebec. Journal of Food Protection 2007; 70: 729–735.
31.Guevremont, E, et al. Antimicrobial susceptibilities of thermophilic Campylobacter from humans, swine, and chicken broilers. Canadian Journal of Veterinary Research 2006; 70: 81–86.
32.Gaudreau, C, Gilbert, H. Antimicrobial resistance of clinical strains of Campylobacter jejuni subsp. jejuni isolates from 1985 to 1997 in Quebec, Canada. Antimicrobial Agents and Chemotherapy 1998; 42: 2106–2108.
33.Smith, KE, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. New England Journal of Medicine 1999; 340: 1525–1532.
34.Nelson, JM, et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. Journal of Infectious Diseases 2004; 190: 1150–1157.
35.Engberg, J, et al. Quinolone-resistant Campylobacter infections in Denmark: risk factors and clinical consequences. Emerging Infectious Diseases 2004; 10: 1056–1063.
36.Evans, MR, et al. Short-term and medium-term clinical outcomes of quinolone-resistant Campylobacter infection. Clinical Infectious Diseases 2009; 48: 1500–1506.
37.Dryden, MS, Gabb, RJ, Wright, SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clinical Infectious Diseases 1996; 22: 1019–1025.
38.Kirkpatrick, BD. Infectious diarrhea. In: Grace, C, ed. Medical Management of Infectious Disease. New York: Marcel Dekker Inc., 2003, pp. 437.
39.Kaplan, MA, et al. Loperamide-simethicone vs loperamide alone, simethicone alone, and placebo in the treatment of acute diarrhea with gas-related abdominal discomfort. A randomized controlled trial. Archives of Family Medicine 1999; 8: 243–248.
40.Li, ST, Grossman, DC, Cummings, P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Medicine 2007; 4: e98.